Portfolio: TVG & APHA awarded Innovate UK grant
Summary by AI BETAClose X
REACH – a non-regulatory announcement
AIM: FIPP
10 November 2026
Frontier IP Group plc
(“Frontier IP” or the “Group”)
Portfolio news – The Vaccine Group and APHA collaborators awarded further Innovate UK grant for BRSV vaccine development
Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company The Vaccine Group Limited (“TVG” or the “Company”) and the UK government’s Animal and Plant Health Agency (“APHA”) have been awarded £500,000 to advance TVG’s bovine respiratory syncytial virus (“BRSV”) vaccine research.
The funding has been awarded through the UK Department for Environment, Food and Rural Affairs’ (“Defra”) Farming Innovation Programme, delivered in partnership with Innovate UK. It will be used to build on the outstanding success enjoyed by two TVG vaccine candidates in Innovate UK Smart-backed trials in calves run by APHA, the results of which were announced in November 2025.
BRSV is a highly contagious and economically damaging disease in cattle globally. The new study will determine the minimum vaccine dose needed to provide effective protection and assess whether this can be achieved following a single vaccination.
As part of the new project, specialist animal health and veterinary group Synergy Farm Health will study the incidence, treatment and associated antibiotic use of bovine respiratory disease in English cattle herds. The findings will help place the vaccine research in its practical farming context and inform future studies.
The Pirbright Institute has estimated the annual cost to British farmers at £54 million, while the global figure could be as much as £5.6 billion*. It is a leading cause of bovine respiratory disease. Frontier IP holds a 16.95 per cent equity stake in the Company, a spin out from the University of Plymouth.
TVG has also reported strong results for a pig vaccine candidate to tackle Streptococcus suis, a zoonotic disease which can cause meningitis, sepsis and other symptoms in humans. The success of the two sets of trials shows that TVG’s novel herpesvirus-based vaccine platform works against both viral and bacterial diseases, and in different animal species.
The Vaccine Group Chief Executive Officer Dr Jeremy Salt said: “We are delighted to continue working with APHA, and with Dr Geraldine Taylor at The Pirbright Institute, who is providing specialist input. The BRSV vaccines have enormous potential and I am optimistic about their commercial prospects.”
Frontier IP Chief Executive Officer Neil Crabb said: “This further funding from Innovate UK and the continued support of APHA is a strong validation of the technology and demonstrates its commercial potential. I look forward to TVG’s next steps.”
*The UK figure is from The Pirbright Institute. The global figure is conservatively based on assumptions that the total cattle population is 1.5 billion; that there are 450 million bovine respiratory cases each year, of which BRSV is responsible for 25 per cent at an average cost of £50 per cow.
ENQUIRIES
Frontier IP Group Plc |
| |
Neil Crabb, Chief Executive Andrew Johnson, Communications and investor relations andrew.johnson@frontierip.co.uk Company website: www.frontierip.co.uk |
M: 07415 888 425 | |
|
| |
Allenby Capital Limited (Nominated Adviser and Joint Broker) Nick Athanas / David Asquith (Corporate Finance) Joscelin Pinnington / Matt Butlin (Corporate Broking)
|
T: 0203 328 5656 | |
Shore Capital (Joint Broker) Henry Willcocks (Corporate Broking) James Thomas / George Payne (Corporate Advisory) |
T: 0207 408 4050
| |
|
| |
The Vaccine Group |
Jeremy.salt@thevaccinegroup.co.uk | |
Jeremy Salt, CEO
|
| |
ABOUT FRONTIER IP
Frontier IP unites science, finance and industry by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 minute ago CLS Holdings
- 9 minutes ago British American Tobacco
- 14 minutes ago British American Tobacco
- 18 minutes ago B.P. Marsh & Partners
- 19 minutes ago British American Tobacco